Search Results

Studies from University of Melbourne Yield New Data on Aldosterone Receptor Antagonists (Effect of spironolactone and cyproterone acetate on breast growth in transgender people: a randomized clinical trial).

• Source: Women's Health Weekly; 10/10/2024, p2575-2575, 1p

Record details

Studies from Shaheed Beheshti University of Medical Sciences Update Current Data on Polycystic Ovary Syndrome (Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women ...)

• Source: Women's Health Weekly. September 19, 2019, 394

Record details

Prescription Appropriateness of Cyproterone Acetate/Ethinylestradiol in Primary Care: A Population-Based Study in Italy.

• Authors : Lapi, Francesco¹; Simonetti, Monica¹; Cricelli, Iacopo¹

Subjects: *CYPROTERONE acetate; *PRIMARY care; *SKIN disease treatmentEUROPEAN Medicines Agency

• Source: Clinical Drug Investigation. Aug2017, Vol. 37 Issue 8, p755-762. 8p.

Record details

Study Results from University of Queensland in the Area of Hormones Reported (How Low Can You Go? Titrating the Lowest Effective Dose of Cyproterone Acetate for Transgender and Gender Diverse People Who Request Feminizing Hormones).

• Source: Women's Health Weekly; 2024, p608-608, 1p

Record details

Studies from Tel Aviv Sourasky Medical Center in the Area of Hormone Replacement Therapy Reported (Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-affirming Hormone Therapy of...).

• Source: Women's Health Weekly; 9/22/2023, p2226-2226, 1p

Record details

New Findings from Ningxia University in the Area of Pyroptosis Described (Cyproterone Acetate Mediates Ire1 Alpha Signaling Pathway To Alleviate Pyroptosis of Ovarian Granulosa Cells Induced By Hyperandrogen).

• Source: Women's Health Weekly; 2/3/2023, p839-839, 1p

Record details

Serum levels of TSP-1, NF-κB and TGF-β1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.

• Authors : Liu, Meimei; Gao, Jiayin; Zhang, Yanhua

Subjects: POLYCYSTIC ovary syndrome; PATIENT management; WOMEN'S health

• Source: Clinical Endocrinology; Dec2015, Vol. 83 Issue 6, p913-922, 10p, 3 Charts, 3 Graphs

Record details

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

• Authors : Vasilakis-Scaramozza, Catherine; Jick, Hershel

Subjects: THROMBOEMBOLISM risk factors; WOMEN'S health; CYPROTERONE acetate

• Source: Lancet. 10/27/2001, Vol. 358 Issue 9291, p1427. 3p. 2 Charts.

Record details

Diane-35 (cyproterone acetate): safety concerns.

• Authors : Wooltorton, Eric

Subjects: VENOUS thrombosis; ORAL contraceptives; THROMBOEMBOLISMUNITED Kingdom

• Source: Canadian Medical Association Journal (CMAJ); 2/18/2003, Vol. 168 Issue 4, p455, 2p, 1 Chart

Record details

Serum High-Sensitivity C-Reactive Protein and Homocysteine Changes During Hormonal Therapy in Women With Polycystic Ovary Syndrome: A Prospective, Matched Study.

• Authors : Makedos, Anastasios; Goulis, Dimitrios G.; Papanikolaou, Alexis

Subjects: C-reactive protein; HOMOCYSTEINE; HORMONE therapy

• Source: Angiology; Aug2010, Vol. 61 Issue 6, p595-601, 7p

Record details